<DOC>
	<DOCNO>NCT01316380</DOCNO>
	<brief_summary>The aim trial evaluate efficacy safety 2.5 5 mcg tiotropium compare placebo 12 week treatment period . Tiotropium inhalation solution deliver via Respimat inhaler examine top maintenance inhale corticosteroid treatment patient mild persistent asthma . Efficacy safety assess measuring effect lung function , effect lung exacerbation , effect asthma control number adverse event .</brief_summary>
	<brief_title>Efficacy Safety 2 Doses Tiotropium Via Respimat Adult Patients With Mild Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient must sign date Informed Consent Form consistent International Conference Harmonisation Good Clinical Practice ( ICHGCP ) guideline local legislation prior participation trial ( i.e . prior trial procedure , include pretrial washout medication medication restriction pulmonary function test Visit 1 ) . 2 . Male female patient age 18 year Visit 0 75 year less Visit 0 . All patient must 3. least 3 month history asthma time enrolment trial . The initial diagnosis asthma must make patient 's age 40 ; 4. prebronchodilator Forced Expiratory Volume 1 second ( FEV1 ) = 60 % predict = 90 % predict normal Visit 1 . Variation absolute FEV1 value Visit 1 ( prebronchodilator ) compare Visit 2 ( predose ) must within ± 30 % . 5 . Patient 's diagnosis asthma confirm Visit 1 bronchodilator reversibility ( within 10 minute pre 1530 minute 400 µg salbutamol/albuterol ) result FEV1 increase = 12 % = 200mL . If achieve reversibility test may repeat within two week . 6 . All patient must symptomatic despite current maintenance treatment low dos inhale corticosteroid . 7 . All patient must symptomatic Visit 1 ( screen ) Visit 2 define Asthma Control Questionnaire ( ACQ ) mean score = 1.5 . 8 . All patient must maintenance treatment low , stable dose inhaled corticosteroid least 4 week prior Visit 1 . 9 . Patients must neversmokers exsmokers stop smoke least one year prior enrolment smoke history le 10 pack year ( ( see Appendix 10.3 calculation ) . 10 . Patients must able use Respimat® inhaler correctly . 11 . Patients must able perform trial related procedure include technically acceptable pulmonary function test use eDiary/peak flow meter ( eDiarycompliance least 80 % require ; refer Section 6.2.1 instruction ) . 12 . Patients take chronic pulmonary medication allow study protocol must willing continue therapy entire duration study ( exception : time acute disease deterioration ) . Exclusion criterion : 1 . Patients significant disease asthma . A significant disease define disease , opinion Investigator , may ( ) put patient risk participation trial , ( ii ) cause concern regard patient 's ability participate trial . 2 . Patients clinically relevant abnormal screening ( Visit 1 ) haematology blood chemistry abnormality define significant disease define exclusion criterion number 1 . 3 . Patients require 10 puff rescue medication ( salbutamol/albuterol MDI ) per 24 hour 2 consecutive day screen period . 4 . Patients recent history ( i.e . six month less ) Acute Coronary Syndrome ( STEMI , NonSTEMI Unstable Angina Pectoris ) . 5 . Patients hospitalise cardiac failure past year . 6 . Patients unstable lifethreatening cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year . 7 . Patients lung disease asthma ( e.g . COPD ) . 8 . Patients know active tuberculosis . 9 . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year . Patients treat basal cell carcinoma allow . 10 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion no.1 . 11 . Patients significant alcohol drug abuse Investigator 's assessment within past two year . 12 . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program 6 week prior Visit 1 ( screen ) . 13 . Patients know hypersensitivity anticholinergic drug , BAC , EDTA components tiotropium inhalation solution . 14 . Pregnant nursing woman , include female patient positive betaHCG test Visit 1 . 15 . Female patient childbearing potential use highly effective method birth control As define ICH ( M3 ) . 16 . Patients treat betablocker medication within four week prior Visit 1 and/or screen period.Topical cardioselective betablocker eye medication nonnarrow angle glaucoma allow . 17 . Patients treat oral patch betaadrenergics , systemic , i.e . oral intravenous corticosteroid , longacting anticholinergic tiotropium ( Spiriva® ) within four week prior Visit 1 and/or screen period . 18 . Patients treat depot corticosteroid within six month prior Visit 1 and/or screen period . 19 . Patients ever treat antiIgE antibody . 20 . Patients treat leukotriene modifier , systemic anticholinergic , cromolyn sodium nedocromil sodium methylxanthines phosphodiesterase 4 inhibitor within two week prior Visit 1 and/or screen period . 21 . Patients treat inhaled long act beta adrenergic long act beta adrenergic combination product within four week prior Visit 0 and/or screen period . 22 . Patients take investigational drug within four week six half life whichever great prior Visit 1 . 23 . Patients treat nonapproved accord international guideline recommend , experimental drug routine asthma therapy ( e.g . TNFalpha blocker , methotrexate , cyclosporin ) within four week prior Visit 1 and/or screen period ( period Visit 1 Visit 2 ) . 24 . Patients asthma exacerbation respiratory tract infection four week prior Visit 1 and/or screen period ( period Visit 1 Visit 2 ) . 25 . Current participation another trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>